Jceler MV2 Tablet ER is an extended-release oral hypoglycemic agent formulated with a combination of Glimepiride (2mg), Metformin (500mg), and Voglibose (0.2mg), designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glycemic control without causing significant hypoglycemia. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the intestine, minimizing postprandial hyperglycemia. The extended-release formulation ensures a sustained therapeutic effect, improving patient compliance by reducing dosing frequency and maintaining stable plasma drug concentrations. Jceler MV2 is indicated as an adjunct to diet and exercise to improve glycemic control in patients inadequately controlled on monotherapy or dual therapy. Caution is advised in patients with renal or hepatic impairment, and it is contraindicated in those with diabetic ketoacidosis or severe metabolic acidosis. Regular monitoring of blood glucose and renal function is recommended during therapy. Adverse effects may include gastrointestinal disturbances, hypoglycemia, and rare hypersensitivity reactions. This combination therapy offers a comprehensive approach to managing hyperglycemia by targeting multiple pathophysiological defects in type 2 diabetes.